Insomnia
Conditions
Interventions
High-altitude insomnia group:Bifidobacterium and Lactobacillus Triple Viable Tablets (Inner Mongolia Shuangqi Pharmaceutical Co., Ltd., specification: 0.5 g per tablet, National Medicine Approval No.
Plain insomnia group:Bifidobacterium and Lactobacillus Triple Viable Tablets (Inner Mongolia Shuangqi Pharmaceutical Co., Ltd., specification: 0.5 g per tablet, National Medicine Approval No. S1998000
High altitude control group:none
Plain control group:none
Sponsors
General Hospital of Western Theater Command
Eligibility
Sex/Gender
Male
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Male military cadres aged 20–50 years stationed at altitudes above 3000 m (high-altitude group) and at municipal units at an altitude of approximately 500 m (plain group). 2. Subjects with a PSQI score > 7 were included in the insomnia subgroup. 3. No antibiotic use within the previous month.
Exclusion criteria
Exclusion criteria: 1. Antibiotic use within the past one month. 2. Gastrointestinal cancer, hematochezia, diarrhea, inflammatory bowel disease, and other digestive system diseases. 3. Comorbidity with other sleep disorders such as sleep apnea hypopnea syndrome in addition to insomnia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Melatonin;GABA;5-HT;Fecal microbiota;Short-chain fatty acids (SCFAs);Pittsburgh Sleep Quality Index (PSQI);Insomnia Severity Index (ISI); | — |
Countries
China
Contacts
Public ContactZheng Wenxue
General Hospital of Western Theater Command
Outcome results
None listed